Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

Conference highlights

Browse highlights from the 2022 European Congress of Rheumatology, June 1–4.

New additions to the Adis Journal Club – June update

Browse June's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

News

Molecular signatures could help guide RA treatment selection

An in-depth molecular analysis of synovial biopsies from people with rheumatoid arthritis who participated in the R4RA trial has identified gene signatures associated with treatment response.

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | COVID-19 & rheumatic disease

04-06-2022 | EULAR 2022 | Conference coverage | News

Support for pausing methotrexate only after second COVID-19 vaccine dose

Pausing methotrexate only after the second dose of a COVID-19 vaccine may provide the best balance between antibody response and risk for flare, findings from two randomized controlled trials suggest.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

IN FOCUS | Inflammatory arthritis

15-06-2022 | Rheumatoid arthritis | News

Molecular signatures could help guide RA treatment selection

An in-depth molecular analysis of synovial biopsies from people with rheumatoid arthritis who participated in the R4RA trial has identified gene signatures associated with treatment response.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

IN FOCUS | Gout and crystal arthropathies

25-01-2022 | Gout | News

​​​​​​​Allopurinol use not linked to increased mortality risk in people with gout, CKD

Individuals with gout and concurrent chronic kidney disease are no more likely to die following allopurinol initiation, dose escalation, or achievement of target serum urate levels than those not taking the drug, study findings indicate.

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

IN FOCUS | JAK inhibitors

01-06-2022 | EULAR 2022 | Conference coverage | News

SELECT-AXIS 2: Upadacitinib shows promise for axSpA

Findings from the SELECT-AXIS 2 trial provide further support for the benefits of upadacitinib across the spectrum of axial spondyloarthritis.

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

IN FOCUS | Lupus

17-05-2022 | Systemic lupus erythematosus | News

Vascular plaque burden could predict future CVD risk in people with SLE

The overall burden of vascular plaque measured on ultrasound scans is significantly associated with future risk for cardiovascular disease events in people with systemic lupus erythematosus, study findings indicate.

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Podcasts

Interviews with expert rheumatologists on patient care